NO930798L - Fremgangsmaate og middel mot tumorer - Google Patents

Fremgangsmaate og middel mot tumorer

Info

Publication number
NO930798L
NO930798L NO93930798A NO930798A NO930798L NO 930798 L NO930798 L NO 930798L NO 93930798 A NO93930798 A NO 93930798A NO 930798 A NO930798 A NO 930798A NO 930798 L NO930798 L NO 930798L
Authority
NO
Norway
Prior art keywords
tumor
tumors
antigen
medicine
procedure
Prior art date
Application number
NO93930798A
Other languages
English (en)
Other versions
NO930798D0 (no
Inventor
Kohji Egawa
Ichiei Sato
Original Assignee
Bio Defense Inst Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bio Defense Inst Co Ltd filed Critical Bio Defense Inst Co Ltd
Publication of NO930798D0 publication Critical patent/NO930798D0/no
Publication of NO930798L publication Critical patent/NO930798L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001111—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

En anti-tumor fremgangsmåte og et anti-tumor middel ved anvendelse av immunreaksjon som er spesifikk for tumor antigener uttrykt på overflaten av tumorceller er beskrevet. Et humant ikke-klassisk histokompatlbilltet klasse l antigen, et antistoff som identifiserer dette antigenet, eller en cytotoksisk lymfocyt blir admini- strert til en cancer pasient som en immunterapi for å indusere resistens overfor tumorer.
NO93930798A 1992-03-05 1993-03-04 Fremgangsmaate og middel mot tumorer NO930798L (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP4048840A JPH05246889A (ja) 1992-03-05 1992-03-05 制癌方法および制癌剤

Publications (2)

Publication Number Publication Date
NO930798D0 NO930798D0 (no) 1993-03-04
NO930798L true NO930798L (no) 1993-09-06

Family

ID=12814449

Family Applications (1)

Application Number Title Priority Date Filing Date
NO93930798A NO930798L (no) 1992-03-05 1993-03-04 Fremgangsmaate og middel mot tumorer

Country Status (15)

Country Link
EP (1) EP0563627A2 (no)
JP (1) JPH05246889A (no)
KR (1) KR930019225A (no)
CN (1) CN1079400A (no)
AU (1) AU3398793A (no)
BR (1) BR9300764A (no)
CA (1) CA2090957A1 (no)
CZ (1) CZ34293A3 (no)
FI (1) FI930976L (no)
HU (1) HUT67859A (no)
IL (1) IL104944A0 (no)
NO (1) NO930798L (no)
NZ (1) NZ247057A (no)
SK (1) SK15993A3 (no)
ZA (1) ZA931558B (no)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6235525B1 (en) * 1991-05-23 2001-05-22 Ludwig Institute For Cancer Research Isolated nucleic acid molecules coding for tumor rejection antigen precursor MAGE-3 and uses thereof
IT1274592B (it) * 1994-08-05 1997-07-18 Angela Turiano Composizione farmaceutica per la terapia tumorale contenente xenoantigeni
UY24367A1 (es) * 1995-11-23 2000-10-31 Boehringer Ingelheim Int Vacunas contra tumores y procedimiento para su produccion
EP0937258A2 (en) * 1996-10-29 1999-08-25 Fred Hutchinson Cancer Research Center, Inc. Cell stress regulated human mhc class i gene
FR2775189B1 (fr) * 1998-07-24 2001-06-08 Commissariat Energie Atomique Compositions anti-tumorales a base d'antigenes hla-g ou d'anticorps anti-hla-g
US6790638B1 (en) * 1998-02-20 2004-09-14 Commissariat A L'energie Atomique Method for selecting tumours expressing HLA-G, sensitive to anticancer treatment and uses
GB9827104D0 (en) * 1998-12-10 1999-02-03 Onyvax Ltd New cancer treatments
EP1245675A1 (en) * 2001-03-28 2002-10-02 Kohji Egawa Cancer cell-specific HLA-F antigen and a diagnostic method of cancer by using thereof
US20050025771A1 (en) * 2003-03-04 2005-02-03 Greenville Hospital System Antitumor agents comprising a targeting portion and an immune response triggering portion

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3825615A1 (de) * 1988-07-28 1990-02-01 Behringwerke Ag Antigenkonstrukte von "major histocompatibility complex" klasse i antigenen mit spezifischen traegermolekuelen, ihre herstellung und verwendung

Also Published As

Publication number Publication date
NO930798D0 (no) 1993-03-04
NZ247057A (en) 1995-10-26
CA2090957A1 (en) 1993-09-06
BR9300764A (pt) 1993-09-28
FI930976A7 (fi) 1993-09-06
HU9300612D0 (en) 1993-05-28
IL104944A0 (en) 1993-07-08
CZ34293A3 (en) 1994-01-19
EP0563627A2 (en) 1993-10-06
ZA931558B (en) 1993-09-27
SK15993A3 (en) 1993-10-06
AU3398793A (en) 1993-09-09
EP0563627A3 (no) 1994-04-27
JPH05246889A (ja) 1993-09-24
FI930976A0 (fi) 1993-03-04
CN1079400A (zh) 1993-12-15
FI930976L (fi) 1993-09-06
HUT67859A (en) 1995-03-23
KR930019225A (ko) 1993-10-18

Similar Documents

Publication Publication Date Title
CA2267157A1 (en) Cancer immunotherapy using tumor cells combined with mixed lymphocytes
AU589351B2 (en) Tumor specific monoclonal antibodies
CA2033640A1 (en) Vaccines against cancer and infectious diseases
AU2006092A (en) Recombinant virus expressing carcinoembryonic antigen and methods of use thereof
GB2210557B (en) Vaccine containing tumor antigens and refined detoxified endotoxin as an adjuvant.
JPS6490200A (en) Bonded body of immunogloblin and cytokine
DK1225870T3 (da) Sammensætning og fremgangsmåde til cancerantigenimmunterapi
EP0719150A4 (en) CELLULAR VACCINE AND METHODS OF USE FOR TREATING MALIGNAS, SOLID TUMORS
AU621830B2 (en) Method and dosage form using an antagonist to gamma interferon to control mhc-associated autoimmune disease
DK0668781T3 (da) Lymfokingenterapi af cancer i kombination med tumorantigener
GR3034908T3 (en) Specific immune system modulation.
AU1716297A (en) Patient-specific immunoadsorbers for the extracorporeal apheresis and methods for their preparation
Gregoire et al. Anti-cancer therapy using dendritic cells and apoptotic tumour cells: pre-clinical data in human mesothelioma and acute myeloid leukaemia
EP0194851A3 (en) Human tumor therapy
Nakamura et al. Immunomodulation by isoprinosine: effects on in vitro immune functions of lymphocytes from humans with autoimmune diseases
AU5781886A (en) Process for the in vitro immunization of human splenocytes against tumor associated antigens
Holmes et al. Immunotherapy of malignancy in humans: Current status
ES8307501A1 (es) "un procedimiento para preparar una forma de dosificacion unitaria adecuada para el tratamiento de una enfermedad asociada con un alelo de un gen de la respuesta inmune".
Yasumoto et al. Randomly controlled study of chemotherapy versus chemoimmunotherapy in postoperative lung cancer patients
KR930019225A (ko) 제암방법 및 제암제
ES2012997A6 (es) Un procedimiento para la obtencion de una linea de celulas hibridas que producen un anticuerpo monoclonal.
Prat et al. Monoclonal antibodies against murine IFN-gamma abrogate in vivo tumor immunity against RSV-induced murine sarcomas.
AU2070688A (en) Antigen recognized by mca 16-88
RU93004625A (ru) Способы лечения, противоопухолевые агенты
Chism et al. Lymphocyte activation in vitro to murine onco-foetal antigens